Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives - PubMed
7 hours ago
- #GLP-1
- #Amycretin
- #Obesity
- Amycretin is a novel unimolecular co-agonist targeting GLP-1 and amylin receptors for weight management.
- It synergistically engages hindbrain-mediated satiety pathways and delays gastric emptying to overcome metabolic plateaus.
- Clinical trials show significant weight reduction: up to 13.1% with oral administration (12 weeks) and 24.3% with subcutaneous delivery (36 weeks).
- Amycretin has a safety profile consistent with incretin-based therapies.
- Potential combination with SGLT2 inhibitors could optimize cardio-renal outcomes.
- Provides a theoretical framework for future management of adiposity-based chronic diseases.